This inventor holds 2 USPTO granted patents. Top assignee: Yoshitomi Pharmaceutical Industries, Ltd.. Active years: 1999-2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Saitama, JP (1999)
- Iruma, JP (2000)
Company Filing History:
Years Active: 1999-2000
Title: Masanori Minoguchi: Innovator in Pharmaceutical Compounds
Introduction
Masanori Minoguchi is a notable inventor based in Iruma, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on benzamide compounds. With a total of 2 patents, his research focuses on therapeutic agents that address various circulatory and respiratory conditions.
Latest Patents
Masanori Minoguchi's latest patents include the development of benzamide compounds and their pharmaceutical applications. These compounds are designed to provide therapeutic benefits for conditions such as hypertension, angina pectoris, asthma, and renal and peripheral circulatory disturbances. The compounds exhibit strong smooth muscle relaxing action and are effective in improving circulation while allowing for oral administration. This innovation presents a promising alternative to conventional calcium antagonists, offering long-lasting effects in the treatment of circulatory diseases.
Career Highlights
Masanori Minoguchi is currently associated with Yoshitomi Pharmaceutical Industries, Ltd., where he continues to advance his research in pharmaceutical sciences. His work has been instrumental in developing new therapeutic agents that enhance patient care and treatment outcomes.
Collaborations
Masanori has collaborated with esteemed colleagues such as Keiji Yamagami and Tadamasa Saitoh. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.
Conclusion
Masanori Minoguchi's contributions to the development of benzamide compounds highlight his commitment to advancing medical science. His work not only addresses critical health issues but also paves the way for future innovations in pharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile